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Abstract: In this study, a series of conformationally restricted thieno[3,2-d]pyrimidinones, 
thieno[3,2-d]pyrimidines and quinazolinones was designed and synthesized with the goal 
of improving the biological activity as 17-hydroxysteroid dehydrogenase type 2 inhibitors 
of the corresponding amidothiophene derivatives. Two moderately active compounds were 
discovered and this allowed the identification of the biologically active open conformer as 
well as the extension of the enzyme binding site characterisation. 
Keywords: thieno[3,2-d]pyrimidinones; thieno[3,2-d]pyrimidines; quinazolinones; 
conformationally restricted analogues; enzyme inhibitors; 17-hydroxysteroid 
dehydrogenase type 2; osteoporosis 
 
1. Introduction 
Osteoporosis is a systemic skeletal disease characterised by reduction of bone mineral density and 
deterioration of the bone microarchitecture leading to an increase in bone fragility and thus elevated 
bone fracture risk [1]. The decrease in active steroid levels like estradiol (E2) and testosterone (T) is 
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often associated with the development of osteoporosis (e.g., in women at menopause [2]). As this 
disease affects elderly men and especially women and the population is getting older, it has become a 
serious public health issue and new therapeutic alternatives have to be developed. 
17-Hydroxysteroid dehydrogenase type 2 (17-HSD2, (EC1.1.1.51) [3]) belongs to the short-chain 
steroid dehydrogenase/reductase protein family (SDR). This enzyme catalyses the NAD+-dependent 
oxidation of the potent estradiol (E2) into estrone (E1) as well as testosterone (T) into androstenedione 
(4-dione). 17-HSD2 is a membrane-associated protein located in the endoplasmic reticulum and 
contains 387 amino acids. This enzyme is highly expressed in a wide variety of tissues such as 
placenta, liver, small intestine, endometrium, urinary tract and to a lesser extend also in kidney, 
pancreas, colon, uterus, breast, prostate and bone. The 3D-structure of this enzyme remains unknown. 
Few 17-HSD2 inhibitors have been described in the literature [4,5]. The concept of improving 
bone quality by inhibiting 17-HSD2 has been validated by Bagi et al. in a monkey osteoporosis 
model [2] using a cis-pyrrolidinone derivative as 17-HSD2 inhibitor [6–8]. However, the treatment 
with this compound led to few effects on bones. Therefore, it is necessary to develop new potent  
17-HSD2 inhibitors with better in vivo efficacy, which are selective toward 17-HSD1, the 
isoenzyme catalysing the reverse reaction, the reduction of E1 into E2 (Figure 1). 
Figure 1. Interconversion of Estradiol (E2) to Estrone (E1) by 17-HSD2 and 17-HSD1. 
 
Our group has been working for 20 years on the development of inhibitors of steroidogenic enzymes 
(e.g., 5-reductase [9], aromatase [10,11], CYP17 [12,13], CYP11B2 [14–17], CYP11B1 [18,19]) and in 
the last years a lot of experience was gained in the design of potent and selective inhibitors of 17-
HSD1 [20–25], and 17-HSD2 [26–32]. Recently, we described [27] N-(3-methoxybenzyl)-5-(3-
methoxyphenyl)-N-methylthiophene-2-carboxamide (compound A, Table 1) and N-(3-hydroxybenzyl)-
5-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide (compound B, Table 1) as 17-HSD2 
inhibitors (63% and 70% 17-HSD2 inhibition at a concentration of 1 µM, for A and B, respectively). Both 
compounds show a good selectivity toward 17-HSD1 (0% and 21% inhibition at 1 µM, respectively). 
Compounds A and B consist of a central thiophene moiety connected to a substituted phenyl ring on one 
side and to a substituted benzyl on the other side linked to the thiophene via a methylated carboxamide 
bond. A and B show some flexibility at this amide bond, allowing for several conformations. 
In the 1H-NMR spectra of A or B it can be seen that the peaks corresponding to N-Me group 
(3.15/3.16 ppm) and to the CH2 of the benzyl group (4.76/4.79 ppm) appear as very broad singlets, 
indicating that in solution at room temperature A and B exist as a mixture of several conformers in 
equilibrium. However, when the compounds bind to the enzyme binding site, only one conformer is 
expected to be present and therefore only one conformer is biologically active. 
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Table 1. In vitro 17-HSD2 and 17-HSD1 inhibitory potencies of thiophene-2-
carboxamide derivatives A and B. 
 
Cmpd R1 R2 
Percentage of inhibition at 1µM a 
17-HSD2 b 17-HSD1 c 
A OMe OMe 63% 0% 
B OH OH 70% 21% 
a Mean value of three determinations, standard deviation less than 15%. b Human placental, microsomal 
fraction, substrate E2 [500 nM], cofactor NAD+ [1500 nM]. c Human placental, cytosolic fraction, substrate 
E1 [500 nM], cofactor NADH [500 nM]. 
Rigidification is an often applied method to increase the potency of active molecules. In addition to 
freezing a compound in one conformation when several exist, it is also a good strategy to identify the 
active conformation of a compound when it binds in the active site of a protein. Rigidification can be a 
useful tool for structural optimisation and also to characterize the binding site in the protein. 
The goal of this study was the structural optimization of the 17-HSD2 inhibitors A and B, using 
the rigidification strategy as well as the identification of the active conformation taken by A and B in 
the protein. In this study the design and the synthesis of new rigidified 17-HSD2 inhibitors, 
mimicking the different geometries which can be adopted by the conformers derived from A and B as 
well as the biological evaluation of the synthesized compounds (17-HSD2 potency as well as 
selectivity toward 17-HSD1) are reported. 
2. Results and Discussion 
Compounds A and B show the highest flexibility at the amide bond, involving two sigma bonds  
(σ1 between the thiophene and the carbonyl moiety and σ2 between the carbonyl and the amino group, 
Figure 2). Since σ bonds are freely rotatable, rotation about the two sigma bonds (σ1 and σ2) of the 
amide group leads to four different conformers I-IV as depicted in Figure 2. The conformational 
freezing of A and B can be achieved by cyclisation leading to thiophene- or phenyl-fused derivatives: 
the thieno[3,2-d]pyrimidin-4-one analogues 1a–b and 3a–d, locked conformers I and III, respectively 
and quinazolin-4-one derivatives 2a–b and 4a–b,locked conformers II and IV, respectively (Figure 3). 
As restrained conformers II and IV are not possible with the thiophene core (S is bivalent), the 
heterocycle was replaced by the bioisosteric phenyl ring (Figure 3). In order to investigate the 
necessity of the benzyl group and its position, compounds 5a–d were designed (conformer I or III), 
and synthesized (Figure 3). 
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Figure 2. Four major conformers of thiophene-2-carboxamide derivatives A and B. 
 
Figure 3. Thieno[3,2-d]pyrimidin-4-ones 1a–b, 3a–d and thieno[3,2-d]pyrimidine 5a–d as 
conformationally restrained analogues of conformer I and III, and quinazolin-4-one 2a–b, 
4a–b as conformationally restrained analogues of conformer II and IV, respectively. 
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Compounds 1a–b were synthesized by a two- or a three-step procedure, respectively, as depicted on 
Scheme 1, starting from compound 6. The starting materials methyl 3-amino-5-(3-methoxyphenyl)- 
thiophene-2-carboxylate (6) and 3-amino-5-(3-methoxyphenyl)thiophene-2-carboxamide (11a) were 
synthesized using the multi-step procedure well described in the literature [33]. The condensation of 
molecule 6 with N,N-dimethylformamide dimethyl acetal (DMF-DMA) gave methyl 3-dimethyl-
aminomethylidene-amino-5-(3-methoxyphenyl)thiophene-2-carboxylate (7) in very good yield [34] 
which was used directly in the next step without purification to afford compound 1a. The condensation of 
6-(3-methoxyphenyl)-4H-thieno[3,2-d][1,3]oxazin-4-one (6a) with 3-methoxybenzyl amine as an 
alternative route to produce 1a failed. After O-demethylation using boron trifluoride methyl sulfide 
complex BF3.SMe2, the thieno[3,2-d]pyrimidin-4(3H)-one 1b was obtained (Scheme 1). 
Scheme 1. Synthesis of the thieno[3,2-d]pyrimidin-4-ones derivatives 1a–b. 
 
Reagents and conditions: (a) DMF-DMA, EtOH, microwave irradiation (100 °C, 80 W, 15 min), 
98%; (b) DMF, microwave irradiation (100 °C, 80 W, 15 min), 31%; (c) BF3.SMe2, CH2Cl2, rt, 
82%; (d) MeOH, reflux. 
Synthesis of derivatives 2a–b was achieved by a three- or a four-step reaction pathway starting 
from the 2-amino-3-bromobenzoic acid (8) as shown on Scheme 2. The starting material 8 was 
prepared as described in the literature [35]. It reacted with triethyl orthoformate [CH(OEt)3] to give the 
cyclized benzoxazin-4-one 9, which was condensed with 3-methoxybenzylamine to afford the quinazolin-
4-one 10 (Scheme 2) [36]. Suzuki-Miyaura cross coupling led to the methoxy derivative 2a in very 
good yield. Ether cleavage using the above described procedure afforded the hydroxylated quinazolin-4-
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one 2b. It is worth mentioning, that the condensation of methyl 2-bromo-6-{[(1E)-
(dimethylamino)methylidene]amino}benzoate (9a) with the 3-methoxybenzyl amine, which was 
successfully applied in the synthesis of the thiophene fused 1a, failed to react to the quinazolin-4-one 10. 
Scheme 2. Synthesis of the quinazolin-4-ones derivatives 2a–b. 
 
Reagents and conditions: (a) CH(OEt)3, microwave irradiation (160 °C, 80 W, 10 min), 61%; (b) dry 
toluene, reflux, 66%; (c) Pd(PPh3)4, Cs2CO3, DME/EtOH/H2O (1:1:1), microwave irradiation  
(150 °C, 150 W, 15 min), 98%; (d) BF3.SMe2, CH2Cl2, rt, 97%. 
Synthesis of 3a–d was performed starting from the 3-amino-5-arylthiophene (11a) as depicted in 
Schemes 3 and 4 following a two- or a three-step procedure. Compound 11a was condensed with  
3-methoxybenzaldehyde in presence of concentrated hydrochloric acid to give first the hydrogenated 
thienopyrimidinone which was then autoxidized to the corresponding thienopyrimidinone 12 on heating in 
acidic medium [37]. Then, N-methylation was performed as previously described to afford 3a. Ether 
cleavage led to the thieno[3,2-d]pyrimidin-4(3H)-one 3b (Scheme 3). 
3-Amino-5-arylthiophene (11a) was also condensed with 3-methoxyphenylacetyl chloride in 
presence of triethylamine. The cyclization step was realized with sodium hydroxide to obtain 13.  
N-methylation was performed using methyliodide in presence of potassium carbonate as base to give 
3c and ether cleavage was accomplished using the same procedure as described above providing 3d in 
very good yield (Scheme 4). 
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Scheme 3. Synthesis of the thieno[3,2-d]pyrimidin-4-ones derivatives 3a–b. 
 
Reagents and conditions: (a) HCl 37%, MeOH, reflux, 38%; (b) MeI, K2CO3, CH3CN, reflux, 
48%; (c) BF3.SMe2, CH2Cl2, rt, 57%. 
Scheme 4. Synthesis of the thieno[3,2-d]pyrimidin-4-ones derivatives 3c–d. 
 
Reagents and conditions: (a) Et3N, dry THF, rt; (b) NaOH 2N, few drops of DMF, reflux, 49% 
(over two steps); (c) MeI, K2CO3, CH3CN, reflux, 74%; (d) BF3.SMe2, CH2Cl2, rt, 98%. 
The 2-substituted quinazolin-4-one 4b was synthesized starting from 2-amino-3-bromobenzoic acid 
methyl ester (14) (Scheme 5), which was reacted with 3-methoxybenzoyl chloride to afford the amide 
15. This intermediate was condensed with formamide to afford the 2-substituted quinazolin-4-one 16 [38]. 
Compound 16 could not be obtained from condensation of 2-amino-6-bromobenzamide (15a) with  
3-methoxybenzaldehyde as described for the synthesis of the thiophene fused derivative 13, even using 
different catalysts (p-toluenesulfonic acid or sodium metabisulfite). This indicates a different reactivity 
of the amino group depending on its location on a thiophene or a phenyl ring. Subsequently, the 
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Suzuki-Miyaura cross coupling led to compound 17, which was then N-methylated at the quinazolin-4-
one into 4a. Treatment with BF3.SMe2 was used to cleave the methoxy groups affording compound 4b. 
Scheme 5. Synthesis of the quinazolin-4-ones derivatives 4a–b. 
 
Reagents and conditions: (a) Et3N, dry CH2Cl2, rt, 15%; (b) H2NCHO, 180 °C, 81%; (c) Pd(PPh3)4, 
Cs2CO3, DME/EtOH/H2O (1:1:1), microwave irradiation (150 °C, 150 W, 15 min), 77%;  
(d) MeI, K2CO3, CH3CN, reflux, 64%; (e) BF3.SMe2, CH2Cl2, rt, 98%. 
The synthesis of fused-compounds 5a–b and 5c–d was performed following two different synthetic 
routes depicted in Scheme 6. The 3-amino-5-arylthiophene amides 11a,b were condensed with formic 
acid under microwave irradiation to afford the corresponding thieno[3,2-d]pyrimidin-4-one 18a,b as 
described in the literature [39]. The conversion of these analogues 18a,b to thieno[3,2-d]pyrimidines 
19a,b was performed using phosphorus oxychloride. The nucleophilic aromatic substitution of 19a, 
19b was accomplished with sodium methylate and gave the desired 4-methoxy-thieno[3,2-
d]pyrimidines 5a and 5b (Scheme 6). Compound 19a was reacted with the corresponding sodium 
methoxyphenolates providing the substituted 4-phenoxythieno[3,2-d]pyrimidines 5c,d, respectively 
(Scheme 6). 
The synthesized compounds were tested for their ability to inhibit 17-HSD2 and 17-HSD1 using 
placental enzymes as previously described (compound concentration: 1 µM) [40]. Results are reported 
in Table 2 as percentage of inhibition. Compounds showing an inhibitory activity below 10% were 
considered as inactive. 
Molecules 2013, 18 4495 
 
 
Scheme 6. Synthesis of the thieno[3,2-d]pyrimidin-4-ones derivatives 5a–d. 
 
Reagents and conditions: (a) HCOOH, H2SO4, 50 °C overnight, 18a: 76%, 18b: 98%; (b) POCl3, 
microwave irradiation (95 °C, 80 W, 20 min), 19a: 98%, 19b: 99%; (c) MeONa in MeOH, DMF, 
rt, 2 h, 5a: 91%, 5b: 40%; (d) sodium 3-methoxyphenolate or sodium 4-methoxyphenolate, DMF 
dry, rt, 2 h, 5c: 88%, 5d: 87%. 
Table 2. In vitro inhibitory potencies toward 17-HSD2 and 17-HSD1 of compounds 1a–b, 
2a–b, 3a–d, 4a–b and 5a–d, 12 and 13. 
Compound 
Percentage of inhibition at 1 µM a 
17-HSD2 b 17-HSD1 c 
1a n.i. n.i. 
1b n.i. n.i. 
2a n.i. n.i. 
2b 11% n.i. 
3a n.i. n.i. 
3b 36% 50% 
3c n.i. n.i. 
3d 25% 48% 
4a n.i. n.i. 
4b n.i. n.i. 
5a n.i. n.i. 
5b n.i. n.i. 
5c n.i. n.i. 
5d n.i. n.i. 
13 n.i. n.i. 
12 n.i. n.i. 
a Mean value of three determinations, standard deviation less than 15%. b Human placental, microsomal 
fraction, substrate E2 [500 nM], cofactor NAD+ [1500 nM]. c Human placental, cytosolic fraction, substrate 
E1 [500 nM], cofactor NADH [500 nM]. d n.i.: no inhibition or inhibition below 10%. 
The most active compounds 3b and 3d show moderate 17-HSD2 inhibition (36% and 25%, 
respectively, Table 2). These two compounds are fused thiophenes and bear two hydroxyphenyl 
moieties. The corresponding methoxy derivatives are inactive. Compounds 3b/3d both result from the 
freezing of conformer III and differ only in the presence of a phenyl or a benzyl group in position 2 of the 
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pyrimidinone. As they are the only active compounds identified in this study, this indicates that 
conformation III is likely to reflect the favourite geometry adapted by compounds A and B in the active 
site of the enzyme, where it is expected that the compounds are present as only one conformer. However, it 
is striking that compounds 3b/3d and B present such a difference in activity (3b: 36% @ 1 M, 3d: 25% 
@ 1 M vs B: 70% @ 1 M). It should be noticed that the corresponding methoxy derivatives 3a and 
3c are inactive, while methoxy compound A has a similar biological activity as the hydroxy compound 
B (A: 63% @ 1 M). One explanation for this finding it that A and B might have a different binding 
mode in the enzyme binding site. 
In order to better understand the biological activities, manual superimposition of 3b and 3d with B 
were made using MOE 2010.10 (considering the lowest energy for each compound, Figure 4). The 
thiophene moiety of 3b/3d was superimposed on the one of B as well as the corresponding carbonyl 
and N-amide moieties. In the superimposition pictures it can be seen that the compounds do not 
overlap exactly with each other (however, they show a better hit than the other conformers). The 
hydroxyphenyl in the 5 position of the fused thiophenes 3b/3d superimposes well on B. The main 
differences concern the second hydroxyphenyl/benzyl which is in a completely different position and 
the presence of the nitrogen N1 of the thienopyrimidinone (absent in A/B). It might be that this polar N 
with hydrogen bond acceptor activity is located in a lipophilic pocket or that there is no space in this 
area to accept the closed thienopyrimidinone ring. These differences might explain the contrasting 
biological activities observed for 3b/3d and B. 
Figure 4. Superimposition between compounds 3b and B (Figure 4-I) and between 
compounds 3d and B (Figure 4-II). 
 
I II 
In Figure 4, it can also be seen that the planarity induced by the rigidified compounds is comparable 
to the planarity of the amide and therefore does not seem to have an impact on the potency of the 
compounds. In this series of compounds the planar triazole derivative C (Figure 5), a cyclised 
bioisostere of the amide function, was synthesized and was also a moderate 17-HSD2 inhibitor with 
inhibitory activity in the same range as 3b/3d (C: 42% @ 1 M, [31]). 
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Figure 5. Described analogues of 3b/3d with rigidified amide bond moiety. 
 
In order to investigate the role of the anisole moiety linked to the thienopyrimidinone, compounds 
5a,c, without OMe-Ph and with OMe-Ph on the O next to the thiophene, respectively, both derived 
from rigidification of conformer I or III, were synthesized. Derivative 5a, without OMe-Ph was 
inactive, indicating the importance of this group, which certainly in case of A is able to interact with 
the active site. Compound 5c, with the OMe-Ph at the O next to the thiophene, was also inactive. This 
anisole moiety, which covers a different area in the active site, might induce a steric clash, preventing 
the binding of the compound in the enzyme binding site. It might indicate that the binding cavity is 
elongated and cannot accommodate globular compounds. This could also explain the inactivity of 
compounds 4a/4b, which have a different geometry compared to 3b/3d.  
The thienopyrimidinones 3b/3d show a structural similarity to compound D [41], previously 
described as 17-HSD1 inhibitor (17-HSD1: 95% inh @ 1 M, 17-HSD2: 77% inh @ 1 M).  
D differs from 3b/3d in the geometry of the pyrimidinone and the OH-Ph fused to the thiophene. As 
observed for D, 3b/3d also shows a slightly better 17-HSD1 inhibition profile.  
The synthesis of the different rigidified conformers highlights a difference in the reactivity of the 
amino group depending on its position on the phenyl ring or on the thiophene moiety. All experiments 
show that the amino group on the thiophene is more reactive than the amino group at the phenyl in 
spite of the fact that phenyl and thiophene are considered to have similar chemical properties. 
3. Experimental  
Chemical names follow IUPAC nomenclature. Starting materials were purchased from Aldrich, 
Acros, Combi-Blocks or Fluka and were used without purification. Flash column chromatography 
(FC) was performed on silica gel (70–200 μm), and reaction progress was monitored by TLC on 
Alugram SIL G/UV254 (Macherey-Nagel). Visualization was accomplished with UV light. 
1H-NMR and 13C-NMR spectra were measured on a Bruker AM500 spectrometer (at 500 MHz and 
125 MHz, respectively) at 300 K in acetone-d6 or DMSO-d6. Chemical shifts are reported in δ (parts 
per million: ppm), by reference to the hydrogenated residues of deuteriated solvent as internal standard: 
2.05 ppm (1H-NMR) and 29.8 and 206.3 ppm (13C-NMR) for acetone-d6, 2.50 ppm (
1H-NMR) and  
39.5 ppm (13C-NMR) for DMSO-d6 and 7.26 ppm (
1H-NMR) and 77.2 ppm (13C-NMR) for CDCl3. 
Signals are described as br (broad), s (singlet), d (doublet), t (triplet), dd (doublet of doublets), ddd (doublet 
of doublet of doublets), dt (doublet of triplets) and m (multiplet). All coupling constants (J) are given in 
Hertz (Hz). Melting points (mp) were measured in open capillaries on a Stuart Scientific SMP3 
apparatus and are uncorrected. 
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Mass spectrometry was performed on a TSQ® Quantum (ThermoFisher, Dreieich, Germany). The 
triple quadrupole mass spectrometer was equipped with an electrospray interface (ESI). The purity of 
the compounds was assessed by LC/MS. The Surveyor®-LC-system consisted of a pump, an auto 
sampler, and a PDA detector. The system was operated by the standard software Xcalibur®. A RP C18 
NUCLEODUR® 100-5 (3 mm) column (Macherey-Nagel GmbH, Dühren, Germany) was used as 
stationary phase. All solvents were HPLC grade. In a gradient run the percentage of acetonitrile 
(containing 0.1% trifluoroacetic acid) was increased from an initial concentration of 0% at 0 min to 
100% at 15 min and kept at 100% for 5 min. The injection volume was 15 µL and flow rate was set to 
800 µL/min. MS analysis was carried out at a needle voltage of 3,000 V and a capillary temperature of 
350 °C. Mass spectra were acquired in positive mode from 100 to 1,000 m/z and UV spectra  
were recorded at the wave length of 254 nm and in some cases at 360 nm. All tested compounds 
exhibited 95% chemical purity. Compounds 6 [20], 8 [22], 11a–b [20] were prepared according to 
previously described procedures. 
3.1. General Procedure for Suzuki — Miyaura Coupling (2a, 17) — Method A  
A solution of 2a or 17 (1 eq.), 3-methoxyphenyl boronic acid (1.5 eq.), cesium carbonate (3 eq.) and 
tetrakis(triphenylphosphine)palladium(0) (0.02 eq.) in oxygen free DME/EtOH/H2O solution (3 mL, 
1:1:1) was heated under microwave irradiation at 150 °C/150 W for 15 min. After cooling to room 
temperature, the mixture water/EtOAc (2 mL, 1:1) was added to quench the reaction. The solution was 
extracted three times by EtOAc (3 × 10 mL). The organic layer was dried over MgSO4, filtered and the 
solution was concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography using n-hexane and EtOAc as eluent. 
3.2. General Procedure for Cleavage of Ethers 1b–4b — Method B  
To a solution of 1a–4a (1 eq.) in CH2Cl2 (10 mL) was added dropwise boron fluoride-dimethyl 
sulfide complex BF3.SMe2 (3 eq./each methoxy group) at 0 °C. After 1 h at 0 °C, the ice bath was 
removed and the reaction mixture was stirred overnight at room temperature. The solution was 
quenched by addition of 10 mL MeOH. After 30 min, the solvent were concentrated under reduced 
pressure at 35 °C and the residue was triturated with cold water. The aqueous layer was extracted three 
times with EtOAc (3 × 15 mL), the organic layer was dried over MgSO4, filtered and the solution 
concentrated under reduced pressure. The residue was purified by silica gel column chromatography 
using n-hexane and EtOAc as eluent or triturated in a mixture of diethylether/petroleum ether and 
filtered off. 
Methyl 3-Amino-5-(3-methoxyphenyl)thiophene-2-Carboxylate (6). To a solution of 3-chloro-3-(3-
methoxyphenyl)prop-2-enenitrile (3.56 g, 18.40 mmol) and dry potassium carbonate (3.05 g, 22.08 mmol) 
in dry NMP (20 mL) was added dropwise under N2 atmosphere methyl thioglycolate (2.01 mL,  
22.08 mmol). The reaction mixture was heated at 60 °C overnight. After cooling, the reaction mixture 
was poured into ice water solution and stirred. The aqueous layer was extracted three times with 
EtOAc (3 × 30 mL). The organic layer was washed once with water, dried over MgSO4, filtered and 
the solution was concentrated under reduced pressure. The residue was purified by silica gel column 
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chromatography (n-hexane/EtOAc 70:30) to afford 6 as a yellow solid. Yield: 50%. Mp: 72–74 °C.  
1H-NMR (CDCl3)  3.84 (s, 3H), 3.85 (s, 3H), 5.47 (br, 2H), 6.76 (s, 1H), 6.90 (dd, J = 1.9, 8.2 Hz, 1H), 
7.10 (t, J = 1.9 Hz, 1H), 7.16–7.19 (m, 1H), 7.30 (t, J = 8.0 Hz, 1H); 13C-NMR (CDCl3)  51.5, 55.6, 111.8, 
114.8, 115.9, 118.8, 130.2, 134.9, 149.2, 154.4, 160.2, 165.2. LC-MS (ESI): [M+H]+ = 264.29. 
Methyl 3-{[(1E)-(dimethylamino)methylidene]amino}-5-(3-methoxyphenyl)thiophene-2-carboxylate (7). 
To a solution of methyl 3-amino-5-(3-methoxyphenyl)thiophene-2-carboxylate 6 (250 mg, 0.95 mmol) in 
EtOH (10 mL) was added N-dimethoxymethyl-N,N-dimethylamine (189 µL, 1.42 mmol). The reaction 
mixture was heated under microwave irradiation at 100 °C/80 W for 30 min. The solution was 
concentrated under reduced pressure to give 7 as an orange oil. Yield: 99%. The title compound was 
used for the next step without further purification. 
3-(3-Methoxybenzyl)-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (1a). A solution of 7  
(302 mg, 0.95 mmol) and 3-methoxybenzylamine (146 µL, 1.14 mmol) in DMF (4 mL) was heated under 
microwave irradiation at 100 °C/80 W for 30 min. Water was added to the solution to quench the 
reaction. The aqueous layer was extracted three times with EtOAc (3 × 15 mL). The organic layer was 
washed once with brine and once with water, dried over MgSO4, filtered and the solution was 
concentrated under reduced pressure. The residue was purified by silica gel column chromatography using 
n-hexane and EtOAc as eluent (n-hexane/EtOAc 60:40) to afford 1a as a pale yellow solid. Yield: 31%. 
Mp: 144–146 °C. 1H-NMR (CDCl3)  3.78 (s, 3H), 3.90 (s, 3H), 5.29 (s, 2H), 6.88 (dd, J = 2.3, 8.2 Hz, 
1H), 6.99–7.05 (m, 3H), 7.28 (t, J = 8.0 Hz, 1H), 7.36–7.44 (m, 3H), 7.68 (s, 1H), 8.48 (s, 1H); 13C-NMR 
(CDCl3)  49.6, 55.4, 55.8, 112.5, 114.1, 114.7, 116.2, 119.5, 120.9, 122.1, 123.2, 130.7, 131.3, 135.3, 
139.4, 150.1, 152.6, 157.4, 158.9, 161.0, 161.4. LC-MS (ESI): [M+H]+ = 379.31. 
3-(3-Hydroxybenzyl)-6-(3-hydroxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (1b). Synthesized according 
to Method B using 1a (52 mg, 0.14 mmol) and BF3.SMe2 (88 µL, 0.84 mmol). The residue was triturated 
in a mixture of diethyl ether/petroleum ether to afford 1b as a pale brown solid. Yield: 82%. Mp:  
270–272 °C. 1H-NMR (DMSO-d6)  5.15 (s, 2H), 6.67 (ddd, J = 0.7, 2.4, 8.0 Hz, 1H), 6.71 (t,  
J = 1.7 Hz, 1H), 6.77 (d, J = 7.7 Hz, 1H), 6.87 (dt, J = 2.0, 7.2 Hz, 1H), 7.14 (t, J = 7.8 Hz, 1H),  
7.17–7.19 (m, 1H), 7.27–7.32 (m, 2H), 7.76 (s, 1H), 8.60 (s, 1H), 9.44 (s, 1H), 9.78 (s, 1H); 13C-NMR 
(DMSO-d6)  48.4, 112.8, 114.2, 114.7, 116.8, 117.0, 118.0, 120.9, 121.4, 129.7, 130.5, 133.6, 138.1, 
149.8, 151.5, 156.2, 157.6, 157.7, 158.0. LC-MS (ESI): [M]+ = 350.84. 
8-Bromo-4H-3,1-benzoxazin-4-one (9). A solution of 2-amino-3-bromobenzoic acid (250 mg, 1.16 mmol) 
and triethyl orthoformate (2 mL) was heated under microwave irradiation at 160 °C/80 W for 15 min. 
After cooling, the precipitate formed was collected by filtration and washed with petroleum ether to afford 
9 as colorless needles. Yield: 61%. Mp: 314–316 °C. 1H-NMR (acetone-d6)  7.57 (t, J = 7.9 Hz, 1H), 8.14 
(s, 1H), 8.17 (dd, J = 1.5, 7.9 Hz, 1H), 8.20 (dd, J = 1.5, 8.0 Hz, 1H); 13C-NMR (acetone-d6)  121.7, 
122.2, 128.6, 130.8, 140.9, 144.6, 152.1, 158.4. 
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8-Bromo-3-(3-methoxybenzyl)quinazolin-4(3H)-one (10). A solution of 9 (100 mg, 0.44 mmol) and  
3-methoxybenzylamine (73 mg, 0.53 mmol) in 2 mL dry toluene was heated at reflux overnight. After 
cooling, the solvent was removed under reduced pressure. The residue was triturated with diethyl ether 
and filtered off to give 10 as a colorless solid. Yield: 66%. Mp: 139–140 °C. 1H-NMR (acetone-d6)  
3.78 (s, 3H), 5.27 (s, 2H), 6.88 (ddd, J = 0.6, 2.6, 8.4 Hz, 1H), 6.99–7.02 (m, 1H), 7.04 (t, J = 2.1 Hz, 1H), 
7.28 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 8.11 (dd, J = 1.5 Hz, 7.8 Hz, 1H), 8.23 (dd, J = 1.5 Hz, 
8.0 Hz, 1H), 8.53 (s, 1H); 13C-NMR (acetone-d6)  50.1, 55.5, 114.2, 114.7, 120.9, 123.1, 124.8, 127.1, 
128.7, 130.7, 138.7, 139.1, 146.9, 149.1, 160.8, 161.0. LC-MS (ESI): [M]+ = 345.46, 347.40. 
3-(3-Methoxybenzyl)-8-(3-methoxyphenyl)quinazolin-4(3H)-one (2a). Synthesized according to 
Method A using 10 (100 mg, 0.29 mmol) and 3-methoxyphenylboronic acid (66 mg, 0.43 mmol). The 
residue was purified by silica gel column chromatography (n-hexane/EtOAc 70:30) to afford 2a as 
colorless oil. Yield: 98%. 1H-NMR (acetone-d6)  3.75 (s, 3H), 3.81 (s, 3H), 5.23 (s, 2H), 6.85 (ddd,  
J = 0.8, 2.6, 8.3 Hz, 1H), 6.94 (ddd, J = 1.0, 2.7, 8.3 Hz, 1H), 6.98–7.01 (m, 1H), 7.04 (t, J = 2.1 Hz, 
1H), 7.16 (ddd, J = 1.0, 1.5, 7.6 Hz, 1H), 7.21 (dd, J = 1.6, 2.5 Hz, 1H), 7.25 (t, J = 7.9 Hz, 1H), 7.33 
(t, J = 8.0 Hz, 1H), 7.56 (t, J = 7.8 Hz, 1H), 7.81 (dd, J = 1.6, 7.4 Hz, 1H), 8.27 (dd, J = 1.6, 8.0 Hz, 
1H), 8.36 (s, 1H); 13C-NMR (acetone-d6)  49.9, 55.56, 55.58, 113.5, 114.1, 114.8, 117.4, 120.9, 
123.7, 123.9, 126.8, 127.7, 129.6, 130.7, 135.8, 139.4, 140.3, 140.9, 146.4, 147.5, 160.1, 161.0, 161.5. 
LC-MS (ESI): [M]+ = 372.77. 
3-(3-Hydroxybenzyl)-8-(3-hydroxyphenyl)quinazolin-4(3H)-one (2b). Synthesized according to 
Method B using 2a (125 mg, 0.31 mmol) and BF3.SMe2 (196 µL, 1.86 mmol). The residue was 
triturated in diethyl ether to afford 2b as a colorless solid. Yield: 97%. Mp: 155–158 °C. 1H-NMR 
(acetone-d6)  5.43 (s, 2H), 6.84 (ddd, J = 0.8, 2.4, 8.1 Hz, 1H), 6.99–7.04 (m, 5H), 7.20–7.23 (m, 1H), 
7.36–7.40 (m, 1H), 7.90 (t, J = 7.7 Hz, 1H), 8.01 (dd, J = 1.5, 7.5 Hz, 1H), 8.40 (dd, J = 1.5, 8.1 Hz, 
1H), 8.43 (br, 1H), 8.67 (br, 1H), 9.48 (s, 1H); 13C-NMR (acetone-d6)  52.6, 116.5, 117.2, 117.4, 
120.7, 121.6, 121.8, 127.9, 130.5, 130.9, 131.6, 135.2, 136.3, 136.5, 136.7, 137.9, 152.1, 158.7, 158.9, 
159.3. LC-MS (ESI): [M]+ = 344.81. 
3-Amino-5-(3-methoxyphenyl)thiophene-2-carboxamide (11a). A solution of sodium sulfide 
nonahydrate Na2S.9H2O (24 g, 100 mmol) in DMF (100 mL) was heated at 40 °C for 30 min. To this 
solution 3-chloro-3-(3-methoxyphenyl)prop-2-enenitrile (9.68 g, 50 mmol) in DMF (20 mL) was 
added. After 2 hours at 50 °C, 2-chloroacetamide (8.42 g, 100 mmol) in DMF (20 mL) was added to 
the reaction mixture. The solution was stirred overnight at 50 °C. Freshly prepared EtONa in EtOH 
(2.30 g of sodium in 30 mL of absolute EtOH) was added to the reaction mixture, which was stirred 
and kept at 50 °C for 2 h. After cooling to room temperature, the mixture was poured into ice water 
solution under stirring. The aqueous layer was extracted three times with EtOAc (3 × 50 mL). The 
organic layer was washed once with water, dried over MgSO4, filtered and the solution was 
concentrated under reduced pressure. The residue was purified by silica gel column chromatography 
(EtOAc 100%) to afford 11a as a pale brown solid. Yield: 21%. Mp: 104–106 °C. 1H-NMR (acetone-d6)  
3.85 (s, 3H), 6.28 (br, 2H), 6.67 (br, 2H), 6.93 (s, 1H), 6.95 (ddd, J = 0.9, 2.6, 8.3 Hz, 1H), 7.16 (t,  
J = 2.1 Hz, 1H), 7.22 (ddd, J = 0.9, 1.6, 7.7 Hz, 1H), 7.34 (t, J = 8.1 Hz, 1H); 13C-NMR (acetone-d6)  
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60.0, 111.1, 116.3, 119.37, 119.43, 123.2, 135.3, 140.4, 154.2, 157.0, 165.4, 166.2. LC-MS (ESI): 
[M]+ = 248.94. 
2,6-Bis(3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (12). A solution of 3-amino-5-(3-
methoxyphenyl)thiophene-2-carboxamide 11a (200 mg, 0.80 mmol), 4-methoxybenzaldehyde  
(117 µL, 0.96 mmol) and concentrated hydrochloric acid 37% (250 µL) was refluxed for 2 hours. After 
cooling, the precipitate was collected by filtration, rinsed with cold MeOH and washed twice with 
diethyl ether to give 12 as a pale brown solid. Yield: 61%. Mp: 241–243 °C. 1H-NMR (DMSO-d6)  
3.86 (s, 3H), 3.88 (s, 3H), 7.03 (ddd, J = 1.3, 2.5, 7.9 Hz, 1H), 7.14 (ddd, J = 0.9, 2.7, 8.3 Hz, 1H), 7.36 (t, 
J = 1.9 Hz, 1H), 7.37–7.47 (m, 3H), 7.71 (t, J = 1.8 Hz, 1H), 7.74 (ddd, J = 0.9, 1.5, 7.7 Hz, 1H), 7.81 
(s, 1H); 13C-NMR (DMSO-d6)  56.0, 56.1, 112.3, 113.5, 116.0, 118.2, 119.2, 120.7, 121.1, 122.0, 
130.2, 131.0, 134.4, 134.5, 151.5, 155.1, 158.5, 158.7, 160.1, 160.6. LC-MS (ESI): [M+H]+ = 365.26. 
2,6-Bis(3-methoxyphenyl)-3-methylthieno[3,2-d]pyrimidin-4(3H)-one (3a). Methyl iodide (20 µL,  
0.32 mmol) was added to a solution of 12 (75 mg, 0.21 mmol) and potassium carbonate (58 mg,  
0.42 mmol) in dry CH3CN (2 mL). The reaction mixture was refluxed for 3 h. After cooling to room 
temperature, the reaction was stopped by adding water. The aqueous layer was extracted three times 
with EtOAc (3 × 5 mL). The organic layer was dried over MgSO4, filtered and the solution was 
concentrated under reduced pressure. The residue was purified by silica TLC using n-hexane and 
EtOAc as eluent (n-hexane/EtOAc 60:40) to afford 3a as a colorless solid. Yield: 48%. Mp:  
148–150 °C. 1H-NMR (CDCl3)  3.54 (s, 3H), 3.871 (s, 3H), 3.873 (s, 3H), 6.96 (ddd, J = 0.8, 2.5,  
8.2 Hz, 1H), 7.05–7.08 (m, 2H), 7.11 (dt, J = 1.2, 7.8 Hz, 1H), 7.23 (t, J = 2.0 Hz, 1H), 7.30 (ddd,  
J = 1.0, 1.4, 7.7 Hz, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.51 (s, 1H). 13C-NMR 
(CDCl3)  34.2, 55.4, 55.5, 112.1, 113.5, 114.9, 115.9, 119.0, 120.2, 120.8, 121.2, 130.1, 130.3, 134.5, 
136.3, 152.5, 156.5, 157.8, 158.5, 159.9, 160.1. LC-MS (ESI): [M+H]+ = 379.29. 
2,6-Bis(3-hydroxyphenyl)-3-methylthieno[3,2-d]pyrimidin-4(3H)-one (3b). Synthesized according to 
Method B using 3a (27 mg, 0.08 mmol) and BF3.SMe2 (51 µL, 0.48 mmol). The residue was triturated 
in a mixture of diethyl ether/petroleum ether to afford 3b as a pale pink solid. Yield: 57%. Mp:  
303–304 °C. 1H-NMR (DMSO-d6)  3.38 (s, 3H), 6.87 (dt, J = 2.0, 7.2 Hz, 1H), 6.94 (ddd, J = 0.8, 2.5,  
8.1 Hz, 1H), 7.00 (t, J = 1.7 Hz, 1H), 7.04–7.06 (m, 1H), 7.19–7.20 (m, 1H), 7.27–7.36 (m, 3H), 7.74 
(s, 1H), 9.78 (br, 2H); 13C-NMR (DMSO-d6)  33.8, 112.7, 115.1, 116.79, 116.81, 117.0, 118.7, 119.8, 120.8, 
129.6, 130.5, 133.7, 136.2, 151.2, 156.4, 157.3, 157.6, 157.99, 158.02. LC-MS (ESI): [M]+ = 350.85. 
2-(4-Methoxybenzyl)-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (13). To a solution of  
3-amino-5-(3-methoxyphenyl)thiophene-2-carboxamide 11a (100 mg, 0.40 mmol) in dry THF (3 mL) 
was added Et3N (67 µL, 0.48 mmol) followed by 4-methoxyphenylacetyl chloride (73 µL, 0.48 mmol). 
The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under reduced 
pressure before NaOH 2N (1.5 mL) and DMF (1.5 mL) were added to the residue. The solution was 
refluxed for 30 min, cooled to room temperature and poured into cold water. The precipitate formed 
was filtered off, washed with water and diethyl ether to give 13 as a colorless solid. Yield: 49%. Mp: 
258–261 °C. 1H-NMR (DMSO-d6)  3.71 (s, 3H), 3.83 (s, 3H), 3.89 (s, 2H), 6.87 (d, J = 8.6 Hz, 2H), 
7.00–7.03 (m, 1H), 7.28 (d, J = 8.6 Hz, 2H), 7.33–7.42 (m, 2H), 7.79 (s, 1H), 12.59 (br, 1H); 13C-NMR 
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(DMSO-d6)  50.0, 60.3, 60.6, 114.6, 116.5, 118.3, 118.6, 119.2, 120.6, 123.7, 125.0, 133.6, 135.2, 
135.8, 139.1, 155.8, 163.4, 163.9, 165.0. LC-MS (ESI): [M+H]+ = 379.22. 
2-(4-Methoxybenzyl)-6-(3-methoxyphenyl)-3-methylthieno[3,2-d]pyrimidin-4(3H)-one (3c). Methyl 
iodide (11 µL, 0.18 mmol) was added to a solution of 13 (46 mg, 0.12 mmol) and potassium carbonate 
(66 mg, 0.24 mmol) in dry CH3CN (2 mL). The reaction mixture was refluxed for 3 hours. After 
cooling to room temperature, the reaction was stopped by adding water. The aqueous layer was 
extracted three times with EtOAc (3 × 5 mL). The organic layer was dried over MgSO4, filtered and 
the solution was concentrated under reduced pressure. The residue was purified by preparative TLC 
using n-hexane and EtOAc as eluent (n-hexane/EtOAc 60:40) to afford 3c as a pale yellow solid. 
Yield: 74%. Mp: 133–134 °C. 1H-NMR (CDCl3)  3.61 (s, 3H), 3.87 (s, 3H), 3.96 (s, 3H), 4.27 (s, 
2H), 6.95 (d, J = 8.7 Hz, 2H), 7.02–7.05 (m, 1H), 7.25 (d, J = 8.7 Hz, 2H), 7.30–7.32 (m, 1H),  
7.34–7.40 (m, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.57 (s, 1H); 13C-NMR (CDCl3)  30.9, 42.0, 55.5, 55.6, 
112.3, 114.7, 115.2, 119.2, 120.8, 121.1, 126.8, 129.6, 130.5, 134.8, 152.5, 156.7, 157.9, 158.7, 159.1, 
160.3. LC-MS (ESI): [M+H]+ = 393.28. 
2-(4-Hydroxybenzyl)-6-(3-hydroxyphenyl)-3-methylthieno[3,2-d]pyrimidin-4(3H)-one (3d). Synthesized 
according to Method B using 3c (35 mg, 0.01 mmol) and BF3.SMe2 (56 µL, 0.54 mmol). The residue 
was triturated in a mixture diethyl ether/petroleum ether to afford 3d as a pale brown solid. Yield: 
98%. Mp: 308–310 °C. 1H-NMR (DMSO-d6)  3.46 (s, 3H), 4.16 (s, 2H), 6.72 (d, J = 7.1 Hz, 2H),  
6.83–6.88 (m, 1H), 7.07 (d, J = 7.1 Hz, 2H), 7.17 (br, 1H), 7.26–7.33 (m, 2H), 7.72 (s, 1H), 9.35  
(s, 1H), 9.79 (s, 1H); 13C-NMR (DMSO-d6)  30.7, 75.4, 111.8, 113.2, 116.0, 117.2, 117.5, 119.7, 121.3, 
125.8, 130.1, 130.9, 134.2, 151.5, 156.7, 157.0, 158.1, 158.5, 159.3. LC-MS (ESI): [M+H]+ = 364.89. 
Methyl 2-amino-3-bromobenzoate (14). A solution of 2-amino-3-bromobenzoic acid 8 (1.033 g,  
4.78 mmol) and thionyl chloride (30 mL) was heated at reflux for 4 hours. After cooling, the solvent 
was reduced under reduced pressure. The residue was poured into MeOH at 0 °C. Excess solvent was 
removed under reduced pressure. The precipitate was filtered and purified by recrystallization in a 
MeOH/water mixture to afford 14 as a yellow solid. Yield: 89%. Mp: 39–40 °C. 1H-NMR  
(Acetone-d6)  3.87 (s, 3H), 6.57 (t, J = 7.8 Hz, 1H), 6.63 (br, 2H), 7.64 (dd, J = 1.6, 7.9 Hz, 1H), 7.85 
(dd, J = 1.5, 8.1 Hz, 1H); 13C-NMR (Acetone-d6)  52.3, 110.8, 112.4, 117.0, 131.6, 138.2, 148.8, 168.5. 
Methyl 3-bromo-2-{[(3-methoxyphenyl)carbonyl]amino}benzoate (15). To a solution of 14 (983 mg, 
4.27 mmol) in dry CH2Cl2 (5 mL) was added Et3N (653 µL, 4.70 mmol) followed by  
3-methoxyphenylacetyl chloride (600 µL, 4.27 mmol). The reaction mixture was stirred at room 
temperature overnight. Water was added to the solution to stop the reaction. The aqueous layer was 
extracted three times with CH2Cl2 (3 × 20 mL). The organic layer was dried over MgSO4, filtered and 
the solution was concentrated under reduced pressure. The residue was purified by silica gel column 
chromatography (n-hexane/EtOAc 95: 5 to 70:30) to afford 15 as a white viscous oil. Yield: 15%. 1H-NMR 
(acetone-d6)  3.78 (s, 3H), 3.89 (s, 3H), 7.18 (ddd, J = 1.0, 2.6, 8.3 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 
7.46 (t, J = 7.7 Hz, 1H), 7.59 (dd, J = 1.6, 2.6 Hz, 1H), 7.64 (ddd, J = 1.0, 1.5, 7.6 Hz, 1H), 7.90 (dd,  
J = 1.5, 7.8 Hz, 1H), 7.93 (dd, J = 1.5, 8.0 Hz, 1H), 9.48 (br, 1H); 13C-NMR (acetone-d6)  52.7, 55.8, 
113.7, 118.6, 120.6, 123.8, 128.4, 130.57, 130.59, 131.0, 136.9, 137.2, 137.4, 160.9, 166.1, 166.8. 
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8-Bromo-2-(3-methoxyphenyl)quinazolin-4(3H)-one (16). A solution of 15 in formamide (5 mL) was 
heated at 180 °C for 6 hours. After cooling, the precipitate formed was dispersed with cold water and 
filtered off. The solid was washed twice with water to give 16 as a pale brown solid. The title 
compound was used for the next step without further purification. Yield: 81%. Mp: 236–239 °C. 1H-NMR 
(DMSO-d6)  3.87 (s, 3H), 7.18 (ddd, J = 1.0, 2.5, 8.2 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.49 (t, J = 8.0 
Hz, 1H), 7.83 (t, J = 1.8 Hz, 1H), 7.88 (ddd, J = 0.9, 1.4, 7.9 Hz, 1H), 8.14 (dd, J = 1.3, 5.4 Hz, 1H), 
8.16 (dd, J = 1.4, 5.3 Hz, 1H), 12.75 (br, 1H); 13C-NMR (DMSO-d6)  55.4, 112.9, 117.8, 120.3, 
122.2, 122.6, 125.7, 127.4, 129.8, 133.6, 137.9, 146.0, 152.6, 159.3, 161.9. LC-MS (ESI): [M]+ = 331.54, 
333.35. 
2,8-Bis(3-methoxyphenyl)quinazolin-4(3H)-one (17). Synthesized according to Method A using 16 
(144 mg, 0.43 mmol) and 3-methoxyphenylboronic acid (98 mg, 0.65 mmol). The residue was purified 
by silica gel column chromatography (n-hexane/EtOAc 70:30) to afford 17 as a colorless solid. Yield: 
77%. Mp: 198–201 °C. 1H-NMR (DMSO-d6)  3.81 (s, 3H), 3.82 (s, 3H), 6.99 (dd, J = 2.0, 8.2 Hz, 
1H), 7.09–7.13 (m, 1H), 7.28 (d, J = 7.7 Hz, 1H), 7.33 (t, J = 2.0 Hz, 1H), 7.39–7.44 (m, 2H), 7.59 (t,  
J = 7.7 Hz, 1H), 7.74–7.77 (m, 2H), 7.90 (dd, J = 1.4, 7.4 Hz, 1H), 8.19 (dd, J = 1.4, 7.9 Hz, 1H), 12.61 
(br, 1H); 13C-NMR (DMSO-d6)  55.0, 55.1, 112.3, 112.9, 116.2, 117.8, 119.8, 121.7, 122.9, 125.4, 126.5, 
128.7, 129.7, 134.1, 135.1, 138.4, 139.6, 145.5, 150.8, 158.7, 159.3, 162.4. LC-MS (ESI): [M]+ = 358.76. 
2,8-Bis(3-methoxyphenyl)-3-methylquinazolin-4(3H)-one (4a). Methyl iodide (29 µL, 0.47 mmol) was 
added to a solution of 17 (112 mg, 0.31 mmol) and potassium carbonate (86 mg, 0.62 mmol) in dry 
CH3CN (3 mL). The reaction mixture was refluxed for 3 h. After cooling to room temperature, the 
solvent was removed under reduced pressure and water was added to the residue to dissolve the 
inorganic salt. The aqueous layer was extracted three times with EtOAc (3 × 5 mL). The organic layer 
was dried over MgSO4, filtered and the solution was concentrated under reduced pressure. The residue 
was purified by silica gel column chromatography using n-hexane and EtOAc as eluent  
(n-hexane/EtOAc 70:30) to afford 4a as a colorless solid. Yield: 64%. Mp: 241–244 °C. 1H-NMR 
(acetone-d6)  3.49 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 6.88 (ddd, J = 1.0, 2.6, 8.2 Hz, 1H), 7.07 (ddd,  
J = 0.9, 2.6, 8.3 Hz, 1H), 7.23 (dt, J = 1.2, 7.7 Hz, 1H), 7.25 (dt, J = 1.1, 7.6 Hz, 1H), 7.28–7.29 (m, 
1H), 7.30 (t, J = 7.8 Hz, 1H), 7.35 (dd, J = 1.7, 2.5 Hz, 1H), 7.43 (t, J = 8.0 Hz, 1H), 7.59 (t, J = 7.7 
Hz, 1H), 7.87 (dd, J = 1.6, 7.5 Hz, 1H), 8.26 (dd, J = 1.6, 7.9 Hz, 1H); 13C-NMR (acetone-d6)  34.4, 
55.5, 55.8, 113.8, 114.8, 116.3, 117.3, 121.3, 122.4, 123.5, 126.7, 127.3, 129.5, 130.4, 135.6, 138.3, 
139.9, 140.9, 145.5, 156.2, 160.0, 160.6, 163.0. LC-MS (ESI): [M]+ = 372.71. 
2,8-Bis(3-hydroxyphenyl)-3-methylquinazolin-4(3H)-one (4b). Synthesized according to Method B 
using 4a (65 mg, 0.17 mmol) and BF3.SMe2 (107 µL, 1.02 mmol). The residue was triturated in diethyl 
ether to afford 4b as a colorless solid. Yield: 98%. Mp: 241–244 °C. 1H-NMR (acetone-d6)  3.48 (s, 
3H), 6.80 (ddd, J = 1.0, 2.6, 8.2 Hz, 1H), 6.98 (ddd, J = 1.0, 2.4, 8.2 Hz, 1H), 7.11–7.15 (m, 3H), 7.18–7.19 
(m, 1H), 7.21 (t, J = 7.8 Hz, 1H), 7.33 (t, J = 8.1 Hz, 1H), 7.56–7.59 (m, 1H), 7.81 (dd, J = 1.7, 7.5 Hz, 
1H), 8.25 (dd, J = 1.6, 8.0 Hz, 1H), 8.35 (s, 1H), 8.75 (s, 1H); 13C-NMR (acetone-d6)  34.4, 115.0, 
116.3, 117.6, 118.5, 120.4, 122.3, 122.7, 126.6, 127.3, 129.5, 130.4, 135.6, 138.2, 140.2, 141.0, 145.6, 
156.3, 157.7, 158.3, 163.1. LC-MS (ESI): [M]+ = 344.77. 
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3.3. General Procedure for the Preparation of Compounds 18a–b — Method C 
A solution of 3-amino-5-(3-methoxyphenyl)thiophene-2-carboxamide 11a (4 mmol) or 3-amino-5-
(4-methoxyphenyl)thiophene-2-carboxamide 11b (4 mmol) in formic acid (10 mL) and with catalytic 
amounts of concentrated sulfuric acid (30 drops) was heated at 50 °C overnight. After cooling, the 
reaction was quenched with cold water and the solid formed was collected by filtration. The residue 
was triturated in diethyl ether and filtered off. 
6-(3-Methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (18a). Synthesized according to Method C 
using 11a (993 mg, 4 mmol) and HCOOH (10 mL). The residue was triturated in diethyl ether to 
afford 18a as a pale green solid. Yield: 76%. Mp: 237–245 °C. 1H-NMR (DMSO-d6)  3.85 (s, 3H), 
7.03 (dt, J = 2.4, 6.9, 1H), 7.38–7.43 (m, 3H), 7.87 (s, 1H), 8.17 (s, 1H), 12.55 (br, 1H); 13C-NMR 
(DMSO-d6)  55.4, 111.5, 115.4, 118.5, 121.5, 122.2, 130.5, 133.8, 147.1, 150.4, 157.0, 158.4, 159.8. 
LC-MS (ESI): [M+H]+ = 259.18. 
6-(4-Methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (18b). Synthesized according to Method C 
using 11b (993 mg, 4 mmol) and HCOOH (10 mL). The residue was triturated in diethyl ether to 
afford 18b as a pale green solid. Yield: 98%. Mp: 296–299 °C. 1H-NMR (DMSO-d6)  3.82 (s, 3H), 
7.04 (d, J = 8.9, 2H), 7.69 (s, 1H), 7.78 (d, J = 8.9, 2H), 8.14 (s, 1H), 12.45 (br, 1H); 13C-NMR 
(DMSO-d6)  55.4, 114.7, 119.7, 121.2, 125.1, 127.6, 146.9, 150.8, 156.9, 158.6, 160.4. LC-MS (ESI): 
[M+H]+ = 259.19. 
3.4. General Procedure for the Preparation of Compounds 19a–b — Method D 
A solution of 6-(3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (18a, 0.58 mmol) or 6-(4-
methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (18b, 0.58 mmol) in phosphorus oxychloride  
(5 mL) was heated under microwave irradiation at 95 °C/80 W for 20 min. Excess of phosphorus 
oxychloride was removed under reduced pressure. Ice was added to the residue and the precipitate 
formed was collected by filtration. The compounds were pure enough and could be used in the next 
step without further purification. 
4-Chloro-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidine (19a). Synthesized according to Method D 
using 18a (150 mg, 0.58 mmol) and POCl3 (5 mL) afforded 19a as a brown solid. Yield: 98%. Mp: 
153–156 °C. 1H-NMR (DMSO-d6)  3.87 (s, 3H), 7.10–7.14 (m, 1H), 7.47 (t, J = 8.2, 1H), 7.51–7.54 
(m, 2H), 8.28 (s, 1H), 9.03 (s, 1H); 13C-NMR (DMSO-d6) 55.5, 111.9, 116.8, 119.2, 120.8, 129.4, 
130.7, 132.9, 153.0, 154.3, 154.8, 159.9, 162.5. LC-MS (ESI): [M+H]+ = 277.17. 
4-Chloro-6-(4-methoxyphenyl)thieno[3,2-d]pyrimidine (19b). Synthesized according to Method D using 
18b (150 mg, 0.58 mmol) and POCl3 (5 mL) afforded 19b as a brown solid. Yield: 99%. Mp: 153–156 °C. 
1H-NMR (DMSO-d6)  3.84 (s, 3H), 7.09 (d, J = 8.7, 2H), 7.92 (d, J = 8.9, 2H), 8.07 (s, 1H), 8.97 (s, 
1H); 13C-NMR (DMSO-d6)  55.5, 114.9, 118.7, 124.1, 128.5, 128.8, 152.6, 154.6, 154.7, 161.4, 
162.9. LC-MS (ESI): [M+H]+ = 277.16. 
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3.5. General Procedure for the Preparation of Compounds 5a–b – Method E 
To a solution of 4-chloro-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidine 19a (0.51 mmol) or  
4-chloro-6-(4-methoxyphenyl)thieno[3,2-d]pyrimidine 19b (0.51 mmol) in dry DMF (2 mL) was 
added sodium methanolate in methanol (0.51 mmol) and the reaction mixture was stirred at room 
temperature for 2 hours. Water was added to quench the reaction. The precipitate formed was collected 
by filtration and washed once with water and once with petroleum ether. 
4-Methoxy-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidine (5a). Synthesized according to Method E 
using 19a (140 mg, 0.51 mmol) and NaOMe (0.51 mmol in 2 mL MeOH). The residue was triturated 
in petroleum ether to afford 5a as a brown solid. Yield: 91%. Mp: 159–162 °C. 1H-NMR (DMSO-d6)  
3.86 (s, 3H), 4.13 (s, 3H), 7.07 (dt, J = 2.3, 7.4 Hz, 1H), 7.42–7.46 (m, 3H), 8.08 (s, 1H), 8.77 (s, 1H); 
13C-NMR (DMSO-d6)  54.2, 55.4, 111.8, 115.9, 116.1, 118.8, 120.5, 130.6, 133.6, 151.3, 154.7, 
159.9, 162.4, 163.5. LC-MS (ESI): [M+H]+ = 273.22. 
4-Methoxy-6-(4-methoxyphenyl)thieno[3,2-d]pyrimidine (5b). Synthesized according to Method E 
using 19b (140 mg, 0.51 mmol) and NaOMe (0.51 mmol in 2 mL MeOH). The residue was triturated 
in petroleum ether to afford 5b as a brown solid. Yield: 40%. Mp: 184–186 °C. 1H-NMR (DMSO-d6)  
3.83 (s, 3H), 4.12 (s, 3H), 7.08 (d, J = 8.8 Hz, 2H), 7.86 (d, J = 8.8 Hz, 2H), 7.91 (s, 1H), 8.74 (s, 1H); 
13C-NMR (DMSO-d6)  54.1, 55.4, 114.8, 115.4, 118.6, 124.8, 128.0, 151.6, 154.7, 160.8, 162.8, 
163.3. LC-MS (ESI): [M+H]+ = 273.21. 
3.6. General Procedure for the Preparation of Compounds 5c–d – Method F 
To a solution of 4-chloro-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidine (19a, 1 eq.) in dry DMF (2 mL) 
was added freshly prepared dry sodium 3-methoxyphenolate or sodium 4-methoxyphenolate (1.2 eq.) 
The reaction mixture was stirred at room temperature for 2 h. Water was added to stop the reaction. 
Organic layer was washed once with NaOH 2N and once with brine, dried over MgSO4, filtered and 
the solution was concentrated under reduced pressure. The precipitate formed was triturated with a 
mixture of petroleum ether / diethyl ether and filtered off. 
4-(3-Methoxyphenoxy)-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidine (5c). Synthesized according to 
Method F using 19a (100 mg, 0.36 mmol) and sodium 3-methoxyphenolate (56 mg, 0.43 mmol). The 
residue was triturated in petroleum ether to afford 5c as a pale brown solid. Yield: 88%. Mp:  
129–132 °C. 1H-NMR (DMSO-d6)  3.78 (s, 3H), 3.87 (s, 3H), 6.92 (dd, J = 2.4, 8.2 Hz, 2H), 6.97 (t, 
J = 2.3 Hz, 1H), 7.09 (ddd, J = 1.1, 1.3, 8.0 Hz, 1H), 7.39 (t, J = 8.2 Hz, 1H), 7.46 (t, J = 8.2 Hz, 1H), 
7.49–7.51 (m, 2H), 8.16 (s, 1H), 8.70 (s, 1H); 13C-NMR (DMSO-d6) 54.4, 55.4, 108.0, 111.86, 
111.87, 114.0, 116.1, 116.3, 118.9, 120.5, 130.2, 130.6, 133.4, 152.3, 152.7, 154.6, 159.9, 160.4, 
163.1, 163.6. LC-MS (ESI): [M+H]+ = 365.26. 
4-(4-Methoxyphenoxy)-6-(3-methoxyphenyl)thieno[3,2-d]pyrimidine (5d). Synthesized according to 
Method F using 19a (30 mg, 0.11 mmol) and sodium 4-methoxyphenolate (17 mg, 0.13 mmol). The 
residue was triturated in petroleum ether to afford 5d as a pale brown solid. Yield: 87%. Mp: 139–146 °C. 
1H-NMR (DMSO-d6)  3.85 (s, 3H), 3.90 (s, 3H), 6.98–7.01 (m, 3H), 7.15–7.17 (m, 1H), 7.20 (t,  
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J = 7.9 Hz, 1H), 7.29 (t, J = 2.0 Hz, 1H), 7.36–7.42 (m, 2H), 7.70 (s, 1H), 8.71 (s, 1H); 13C-NMR 
(DMSO-d6) 55.4, 55.6, 112.5, 114.8, 115.4, 117.4, 119.3, 120.0, 122.7, 130.4, 134.3, 145.4, 153.2, 
154.8, 157.5, 160.2, 163.6, 164.0. LC-MS (ESI): [M+H]+ = 365.25. 
4. Conclusions  
In this study, a series of six thieno[3,2-d]pyrimidin-4-ones, four thieno[3,2-d]pyrimidines and four 
quinazolin-4-ones was synthesized and tested for 17-HSD2 and 17-HSD1 inhibition. Two 
compounds 3b and 3d were identified as moderate 17-HSD2 inhibitors, 3b being the best one with an 
inhibition of 36% at 1 µM. These compounds resulted from the rigidification of conformer III, which 
can be considered as the active conformer in the enzyme binding site. The inactive globular 
compounds like 4a/4b or 5c/5d are indicative of the enzyme binding site being rather elongated and 
are tools to further characterize the 17-HSD2 active site. Compounds 3b/3d need further optimization 
focussing on conformer III and exchanging the geometry of the pyrimidinone or replacing the polar 
nitrogen of the pyrimidinone moiety by a carbon or reducing the size of the ring fused to the thiophene.  
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